Biotech’s Flublok is only FDA-approved cell-based flu jab
Could French biotech snap up remaining rights to pancreatic cancer drug?
Big projects are priority as threat from generic Advair looms.
Sucampo gains rights to a drug for rare genetic disorder.
Japanese pharma swoops after strong phase 2a results.
Deal set to close in Q2.
Phase 3 data confirmed its efficacy in patients with a certain mutation.